Integrating Tech with Preventative Medical Care: An Interview with Quantgene CEO Jo Bhakdi
Impakter had the opportunity to speak with Jo Bhakdi, founder and CEO of Quantgene. The company aims to transform the medical paradigm by creating a new system of premium preventative care, powered by advanced technology.
Over the past decade or so, technological advancements in medical research have been increasingly outpacing their application to standard medical practice. New diagnostics, drugs, and devices are being held up by decade-long payer assessments.
Medical innovations are met with high hurdles in going to market. The companies responsible for developing these novel technologies not only have to demonstrate that they will protect the patients’ health, but that they will cut costs as well. As a result, physicians often don’t have access to the most advanced resources that could potentially have a profound impact on patient outcomes.
“The silos among biotechnology development, clinical procedures, data management, and healthcare economics have to be broken down,” said Jo. “They need to be merged into one vertically integrated innovation stack that has only one goal: to protect the patient from disease.”
The first significant development that Quantgene plans to introduce in 2020 is its proprietary deep sequencing and AI system, which has been designed to detect 8 deadly cancers at the earliest stages in the blood.
Detecting cancer early has been shown to increase survivability by approximately 61% across 10 of the most common cancer types. This not only saves lives but alleviates the burden, both physical and financial, on families and the nation’s healthcare system as a whole.
In the picture: Cell-free DNA (cfDNA) is loaded into the Qiasymphony machine for extraction. Photo Credit: Quantgene
According to Jo, “Early cancer detection is the single biggest key lever we have to improve protection against unfavorable outcomes.” He then added, “We have brought together the technology and medical infrastructure with the goal of providing our members access to this protection today.”
Through the 2020 launch and implementation of Quantgene’s premium preventative care system, Serenity, patients will have access to the guidance and recommendations of leading physicians as well as the latest scientific advancements.
The process begins with a simple blood draw. Keeping with the philosophy of executing on a patient-centric model, Serenity sends a mobile phlebotomist to the patient’s home or workplace. Then, a proprietary cfDNA extraction process takes place, genes are identified, and Illumina NovaSeq ultra-deep sequencing system captures individual mutations at single-molecule precision.
In the picture: Library preparation using PCR (or polymerase chain reactions) to amplify target segments of DNA. Primers are attached to these targets and go through more than 10 doubling cycles. Photo Credit: Quantgene.
The process is completed by loading these genomic data sets, alongside medical records, into Quantgene’s AI/ machine learning system to capture somatic tumor-associated mutations down to a 0.1% mutant allele frequency, or MAF. This means that the system can identify a single fragment of tumor DNA out of one thousand healthy copies. Expert physician consultation and follow up is then provided through Serenity’s telehealth system, and patients are guided in their personalized treatment options.
Although Quantgene sees cancer diagnostics as being the most pressing concern, in the near future, they are hoping to utilize the technology to identify a variety of different chronic, degenerative diseases. This would potentially include cardiovascular disease and a number of inflammatory conditions. Additionally, the company is opening up the usage of their proprietary technology to others interested in conducting liquid biopsy research.